A Phase I Dose Escalation Trial of Weekly Intravenous Administrations of BI 836845 in Patients With Advanced Solid Cancers With Repeated Administrations in Patients Showing Clinical Benefit.
Phase of Trial: Phase I
Latest Information Update: 27 Jan 2016
At a glance
- Drugs Xentuzumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 07 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 23 Sep 2015 Status changed from completed to active, no longer recruiting as per ClinicalTrials.gov record.
- 30 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.